EMA Sets Date For Quinolone, Fluoroquinolone Public Hearing
Executive Summary
People interested in participating in the European Medicines Agency’s second ever public hearing and sharing their experiences about the risks associated with quinolone and fluoroquinolone antibiotics must register to do so no later than April 30.
You may also be interested in...
Huge Interest In EMA's Public Hearing On Side-Effects Of Quinolones, Fluoroquinolones
The European Medicines Agency has chosen 23 speakers from 55 requests made by people interested in sharing their experiences with the use of these widely-prescribed antibiotics.
EMA Calls For Visual Warnings Among Measures To Restrict Valproate Use
The European Medicines Agency has recommended that EU member states should introduce further restrictions on the use of valproate-containing medicines to avoid the drug's exposure in pregnancy.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.